The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,170,292 in first-year total cost, median $397,500.
Most frequent study sections
- Special Emphasis Panel[ZAR1 KM (M2)]7
- Special Emphasis Panel[ZAR1 YL (M1)]6
Most frequent institutions
- CINCINNATI CHILDRENS HOSP MED CTR2
- EAST CAROLINA UNIVERSITY1
- MASSACHUSETTS GENERAL HOSPITAL1
- OHIO STATE UNIVERSITY1
- OKLAHOMA MEDICAL RESEARCH FOUNDATION1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Intraarticular microbial DNA as a novel mediator of osteoarthritis1R61AR078075-01 | JEFFRIES, MATLOCK | OKLAHOMA MEDICAL RESEARCH FOUNDATION, OK | $437,000 | ZAR1 |
| 2020 | Electrical Coupling of Circulating Immune Cells to Peripheral Tissues1R61AR078060-01 | JANKOWSKI, MICHAEL P | CINCINNATI CHILDRENS HOSP MED CTR, OH | $413,371 | ZAR1 |
| 2020 | Neutrophil Biomarker and neutrophil targeted therapy to predict and prevent heterotopic ossification1R61AR078072-01 | LEVI, BENJAMIN | UT SOUTHWESTERN MEDICAL CENTER, TX | $408,750 | ZAR1 |
| 2020 | Walk this way: leveraging of a unique skeletal muscle that is resistant to ischemic injury1R61AR078100-01 | SPANGENBURG, ESPEN E | EAST CAROLINA UNIVERSITY, NC | $382,806 | ZAR1 |
| 2020 | A new model for spatio-temporal coupling of bone formation and bone resorption governed by osteoclasts1R61AR078073-01 | MISHINA, YUJIPARK, DONGSUWEIVODA, MEGAN M | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $359,200 | ZAR1 |
| 2020 | Muscle-driven, implanted endoprostheses for musculoskeletal limb reconstruction1R61AR078096-01 | CROUCH, DUSTIN L. | UNIVERSITY OF TENNESSEE KNOXVILLE, TN | $339,636 | ZAR1 |
| 2019 | Transforming Neuromuscular Diagnosis and Treatment by Virtual Muscle Biopsy (VBx)1R61AR076787-01 | LIEBER, RICHARD L. | REHABILITATION INSTITUTE OF CHICAGO D/B/A SHIRLEY RYAN ABILITYLAB, IL | $471,469 | ZAR1 |
| 2019 | Manipulation of Sox9-positive osteochondroprogenitor cells towards cell-based gene therapy for genetic bone diseases.1R61AR076775-01 | KOBAYASHI, TATSUYA | MASSACHUSETTS GENERAL HOSPITAL, MA | $403,291 | ZAR1 |
| 2019 | Targeting the Notch3 Mutation to Cure Lehman Syndrome1R61AR076747-01 | CANALIS, ERNESTO | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $402,973 | ZAR1 |
| 2019 | Improving delivery of therapeutic material to skeletal muscle1R61AR076771-01 | MILLAY, DOUGLAS PAUL | CINCINNATI CHILDRENS HOSP MED CTR, OH | $397,500 | ZAR1 |
| 2019 | Repressing Retrotransposon LINE-1: New Concepts for Osteoarthritis Treatment1R61AR076807-01 | CHEN, QIAN | RHODE ISLAND HOSPITAL, RI | $393,790 | ZAR1 |
| 2019 | Engineering smart cells for arthritis therapy1R61AR076820-01 | GUILAK, FARSHIDPHAM, CHRISTINE T. | WASHINGTON UNIVERSITY, MO | $392,761 | ZAR1 |
| 2019 | Non-viral Reprogramming of Intervertebral Disc Cells for the treatment of Discogenic back pain1R61AR076786-01 | HIGUITA-CASTRO, NATALIAPURMESSUR (WALTER), DEVINA | OHIO STATE UNIVERSITY, OH | $367,745 | ZAR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.